Turn Your Side Hustle Into a 7-Figure Business With These 4 AI Growth Hacks
Opinions expressed by Entrepreneur contributors are their own.
Most entrepreneurs are using AI the wrong way — tweaking blog posts, drafting emails and hoping it saves time. But surface-level tools won't grow your business. What if you could use AI to build a system that runs your content, lead gen and sales — without hiring a single person?
This video reveals the four high-leverage AI growth hacks that solo entrepreneurs are using to reclaim three days a week and scale to seven figures — no tech skills required. What you'll discover:
The content research shortcut top creators swear by: Uncover high-converting ideas from what's already working in your niche — then turn those insights into original, engaging content in record time.
Uncover high-converting ideas from what's already working in your niche — then turn those insights into original, engaging content in record time. Your always-on sales assistant: Deploy a smart system that engages leads, answers questions and handles objections — boosting conversions while you focus on growth.
Deploy a smart system that engages leads, answers questions and handles objections — boosting conversions while you focus on growth. Lead generation on autopilot: Set up a full cold outreach engine that identifies ideal prospects, warms them up and keeps conversations moving — without the manual grind.
Set up a full cold outreach engine that identifies ideal prospects, warms them up and keeps conversations moving — without the manual grind. Revenue-boosting email intelligence: Analyze your past campaign data to reveal exactly what drives clicks and sales — then use AI to write emails that outperform your best ones.
Analyze your past campaign data to reveal exactly what drives clicks and sales — then use AI to write emails that outperform your best ones. The plug-and-play system behind seven-figure solopreneurs: Link these automations together to build a lean, self-sustaining business engine that grows even when you're offline.
Everything is broken down step-by-step, no tech skills required. If you're ready to scale your business without burning out, this is the video to watch.
Download the free "AI Success Kit" (limited time only). And you'll also get a free chapter from my brand new book, "The Wolf is at The Door - How to Survive and Thrive in an AI-Driven World."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
17 minutes ago
- Medscape
Which Class of ER Degrader Is Better?
Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), outshone the commonly used selective estrogen receptor degrader (SERD) fulvestrant in a phase 3 trial of second-line treatment for a subset of patients with breast cancer. The VERITAC-2 trial included patients with ER-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-), locally advanced or metastatic disease who had failed prior treatment with cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors and endocrine therapy, and no exposure to chemotherapy in the advanced setting. Only a subset of the study cohort, those with estrogen receptor 1-mutant disease, experienced a statistically significant and clinically meaningful improvement in progression-free survival (PFS) when treated with vepdegestrant compared with patients treated with fulvestrant. 'These results support vepdegestrant as a potential monotherapy treatment option for patients with previously treated ESR1 -mutant ER+/HER2- advanced breast cancer,' said lead author Erika P. Hamilton, MD, a medical oncologist and director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, Nashville, Tennessee, during a press conference for the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings were simultaneously published in the New England Journal of Medicine . Vepdegestrant is not approved by the US Food and Drug Administration, but received fast-track status in February 2024 as monotherapy for this patient population. It is the first and only PROTAC ER degrader to be evaluated in a phase 3 clinical trial in breast cancer. PROTACs represent a novel class of therapeutic agents that harness the proteasome to selectively degrade target proteins. 'There's no established consensus for patients getting treatment in the second-line setting after progression on endocrine therapy and a CDK 4/6 inhibitor,' explained Hamilton. 'One of the mainstays of our treatment really has been fulvestrant, which clearly has some challenges. First, it's administered intramuscularly, and second, in a post-CDK 4/6 landscape, we know that progression-free survival is very short — on the order of less than 2 months.' Besides fulvestrant, the oral SERD elacestrant was FDA-approved in January 2023, and other oral SERDs are in development, she noted. Trial Design The new trial included 624 patients with advanced ER+/HER2- disease that had progressed following one or two lines of endocrine therapy and a CDK 4/6 inhibitor. 'They could not have received fulvestrant already or chemotherapy, and patients had to have benefited from their previous line of endocrine therapy for at least 6 months to enter the study,' Hamilton noted. Study participants were also stratified by the presence or absence of visceral disease, as well as the presence of an ESR1 mutation (n = 270). Such mutations are a common cause of acquired resistance found in approximately 40% of patients in the second-line setting, according to a press release from the drug developer. Patients were randomly assigned 1:1 to 28-day treatment cycles of either 200 mg oral vepdegestrant once daily, or 500 mg intramuscular fulvestrant on day 1 and day 15 of the first cycle, and then on day 1 of each subsequent cycle. The primary endpoint was PFS by blinded, independent central review, first in patients with ESR1 mutations and then in the entire cohort. Key secondary endpoints were overall survival, objective response rate, and clinical benefit rate, which was defined as the rate of confirmed clinical or partial response at any time, or stable disease, nonclinical response, or nonprogressive disease for at least 24 weeks. Vepdegestrant vs Fulvestrant The study met its key primary endpoint, showing a median PFS of 5.0 months with vepdegestrant compared with 2.1 months with fulvestrant (hazard ratio [HR] 0.57; P < .001) in the 270 patients with ESR1 mutations. At 6 months, twice as many patients in the vepdegestrant arm remained progression-free compared with those in the fulvestrant arm (45.2% vs 22.7%). However, this primary endpoint was not significantly different between groups when calculated for the entire patient population (HR, 0.83; P = .07). For the key secondary endpoints, among patients with ESR1 mutations, the clinical benefit rate was more than double in patients receiving vepdegestrant (42.1% vs 20.2%). Similarly, the objective response rate was more than four times higher (18.6% vs 4%) Commenting in a press release, ASCO breast cancer expert Jane Lowe Meisel, MD, said that although the trial found that vepdegestrant worked better than fulvestrant in patients with ESR1 mutations, 'on average, patients did not have prolonged responses on either agent, highlighting the need for combination therapies and continued development in this space.' Meisel is co-director of Breast Medical Oncology at the Winship Cancer Institute of Emory University School of Medicine in Atlanta, Georgia. 'Overall survival was very immature at the time of this analysis, with only 20% of the anticipated events occurring,' added lead investigator Hamilton. Treatment-emergent adverse events (TEAEs) led to discontinuation in 3% of patients taking vepdegestrant and 1% of patients taking fulvestrant. TEAEs leading to dose reductions occurred in 2% of the vepdegestrant group and none in the fulvestrant group. The three most common AEs of any grade were fatigue (27% in vepdegestrant group, 16% fulvestrant group) and increased aspartate aminotransferase and alanine aminotransferase levels of any grade (14% vepdegestrant group, 10% fulvestrant group). Oral SERDS vs Vepdegestrant Side Effects Compared to oral SERDs, vepdegestrant has a favorable side effect profile, Hamilton said. 'Oral SERDs have prominent GI side effects as their most frequent side effect.' But, across all grades, rates of both vomiting and diarrhea were only 6% with vepdegestrant. GI side effects tend to be more common, 'in the 30% or 40% range with oral SERDs,' she told Medscape Medical News . Study discussant William John Gradishar, MD, emphasized the importance of reducing side effects. ' Vepdegestrant now joins a growing list of drugs that perform better than current standard of care monotherapy' in the ESR1 -mutant population, he noted in the session. But the reality is that most of these drugs are being developed to be used in combination with targeted therapies, 'and increased toxicity can be expected with doublet therapy…Quality of life measures as experienced and reported by patients are critical, and even modest changes in symptom and functional domains should not be minimized,' said Gradishar, professor of breast oncology at Northwestern University Feinberg School of Medicine, Chicago, Illinois. 'Vepdegestrant has demonstrated compelling preclinical activity and encouraging early clinical data supporting its efficacy in degrading ER,' said Albert Grinshpun, MD, in an interview with Medscape Medical News . Grinshpun, head of the Breast Cancer Service at Shaare Zedek Medical Center and The Hebrew University, Jerusalem, Israel, said his initial takeaway from the study is that 'vepdegestrant now stands alongside other oral SERDs, such as elacestrant and imlunestrant, in demonstrating superiority over fulvestrant, specifically in the context of ESR1 -mutant [disease].' 'Importantly, the treatment landscape for patients progressing on CDK 4/6 inhibitors is rapidly evolving, with a growing shift toward combination therapies rather than fulvestrant monotherapy,' he said. 'In my view, vepdegestrant has established itself as a promising endocrine backbone for future combination strategies. Its favorable toxicity profile makes it particularly well-suited for pairing with a range of targeted agents or even antibody-drug conjugates, including inhibitors of PIK3CA and KAT6 , in the pursuit of more effective therapeutic regimens.' The study was jointly funded by Arvinas Estrogen Receptor, Inc. and Pfizer. Hamilton disclosed consulting or advisory roles with Accutar Biotechnology (Inst), Arvinas (Inst), AstraZeneca (Inst), Circle Pharma (Inst), Daiichi Sankyo (Inst), Ellipses Pharma (Inst), Entos (Inst), Fosun Pharma (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), Janssen (Inst), Jazz Pharmaceuticals (Inst), Jefferies (Inst), Johnson & Johnson (Inst), Lilly (Inst), Medical Pharma Services (Inst), Mersana (Inst), Novartis (Inst), Olema Pharmaceuticals (Inst), Pfizer (Inst), Stemline Therapeutics (Inst), Tempus (Inst), Theratechnologies (Inst), Tubulis GmbH (Inst), Verascity Science (Inst), and Zentalis (Inst). Hamilton has also received research funding from AbbVie (Inst), Accutar Biotech (Inst), Acerta Pharma (Inst), ADC Therapeutics (Inst), Akeso Biopharma (Inst), Amgen (Inst), Aravive (Inst), ArQule (Inst), Artios (Inst), Arvinas (Inst), AstraZeneca (Inst), AtlasMedx (Inst), BeiGene (Inst), Black Diamond Therapeutics (Inst), Bliss Biopharmaceutical (Inst), Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Cascadian Therapeutics (Inst), Clovis Oncology (Inst), Compugen (Inst), Context Therapeutics (Inst), Cullinan Oncology (Inst), Curis (Inst), CytomX Therapeutics (Inst), Daiichi Sankyo (Inst), Dana-Farber Cancer Institute (Inst), Dantari (Inst), Deciphera (Inst), Duality Biologics (Inst), eFFECTOR Therapeutics (Inst), Eisai (Inst), Ellipses Pharma (Inst), Elucida Oncology (Inst), EMD Serono (Inst), Fochon Pharmaceuticals (Inst), Fujifilm (Inst), G1 Therapeutics (Inst), Genentech/Roche (Inst), Gilead Sciences (Inst), H3 Biomedicine (Inst), Harpoon (Inst), Hutchison MediPharma (Inst), Immunogen (Inst), Immunomedics (Inst), Incyte (Inst), Infinity Pharmaceuticals (Inst), Inspirna (Inst), InventisBio (Inst), Jacobio (Inst), K-Group Beta (Inst), Karyopharm Therapeutics (Inst), Kind Pharmaceuticals (Inst), Leap Therapeutics (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), MabSpace Biosciences (Inst), Macrogenics (Inst), MedImmune (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Molecular Templates (Inst), Myriad Genetics (Inst), Novartis (Inst), Nucana (Inst), Olema Pharmaceuticals (Inst), OncoMed (Inst), Oncothyreon (Inst), ORIC Pharmaceuticals (Inst), Orinove (Inst), Orum Therapeutics (Inst), Pfizer (Inst), PharmaMar (Inst), Pieris Pharmaceuticals (Inst), Pionyr (Inst), Plexxikon (Inst), Prelude Therapeutics (Inst), ProfoundBio (Inst), Radius Health (Inst), Regeneron (Inst), Relay Therapeutics (Inst), Repertoire Immune Medicines (Inst), Rgenix (Inst), Seagen (Inst), Sermonix Pharmaceuticals (Inst), Shattuck Labs (Inst), Silverback Therapeutics (Inst), Stem CentRx (Inst), Stemline Therapeutics (Inst), Sutro Biopharma (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), TapImmune Inc. (Inst), Tesaro (Inst), Tolmar (Inst), Torque (Inst), Treadwell Therapeutics (Inst), Verastem (Inst), Zenith Epigenetics (Inst), and Zymeworks (Inst). Meisel disclosed consulting or advisory roles with AstraZeneca, GE Healthcare, Genentech, Novartis, Olema Oncology, Pfizer, SeaGen, Sermonix Pharmaceuticals, and Stemline, and research funding from AstraZeneca (Inst), Olema Oncology (Inst), Pfizer (Inst), Seagen (Inst), and Sermonix Pharmaceuticals (Inst). Grinshpun disclosed honoraria from GSK, Lilly, Novartis, and AstraZeneca, and travel from Roche, Pfizer, and AstraZeneca. Gradishar disclosed consulting or advisory roles with AstraZeneca , Genentech/Roche, Gilead Sciences, Merck, Novartis, Pfizer.
Forbes
22 minutes ago
- Forbes
Elon Musk Doesn't Agree With Every Trump Administration Action
Elon Musk—a key adviser to President Donald Trump who left his formal role in the government Friday—said in an interview with CBS News earlier in the week he thought criticism of his Department of Government Efficiency was 'unfair' and said he doesn't want to 'take responsibility for everything this administration's doing.' President Donald Trump speaks during a news conference with Elon Musk on May 30, 2025 inside the ... More Oval Office at the White House in Washington. During an interview with CBS News, Musk initially shied away from questions about the impact of Trump's tariffs on his businesses before openly discussing DOGE and what he said were 'unfair' criticisms. 'If there was some cut, real or imagined, everyone would blame DOGE,' Musk told CBS News' David Pogue. He went on to discuss the administration more broadly, saying, 'it's not like I agree with everything the administration does … So it's like, I mean, I agree with much of what the administration does. But we have differences of opinion.' Musk said he doesn't want to 'take responsibility for everything this administration's doing,' but if he brought up his disagreements publicly it 'creates a bone of contention,' saying, 'I'm a little stuck in a bind.' On Tuesday, CBS News released a clip of the interview in which Musk criticized the 'big, beautiful bill' Trump has been advocating for in Congress. The clip showed Musk saying he was 'disappointed' about the bill, which he said 'increases the budget deficit, not just decreases it, and undermines the work that the DOGE team is doing.' The comments quickly made headlines, and the following day Musk confirmed his official departure from the government. Musk endorsed Trump and became a megadonor after an assassination attempt on the president while he was campaigning in July, and Musk ended up giving more than $200 million to help Trump get elected. After he won a second term in November, Trump announced Musk would lead the Department of Government Efficiency, which the president said would 'slash excess regulations, cut wasteful expenditures, and restructure Federal Agencies.' Musk became a special government employee—which limited his service term to 130 days—when Trump was inaugurated, and he began the work of slashing the federal workforce and spending. DOGE's work—which included laying off hundreds of thousands of federal employees—drew bipartisan criticism and a number of legal challenges that are still playing out in court. Trump regularly praised Musk, though, and Friday when the pair were discussing Musk's government departure, Trump thanked Musk for the 'colossal change' DOGE spearheaded and said he thinks Musk will continue helping the government. 'I'll continue to be visiting here and be a friend and adviser' to Trump, Musk said Friday at a press conference with the president. $2 trillion. That's initially how much Musk said DOGE would save the government, though he later lowered the estimate to $1 trillion. DOGE's website claims it has so far saved the government an estimated $175 billion, though the website has frequently featured errors like counting contracts multiple times, using 'billions' when it meant to report 'millions,' and more, according to The New York Times. A reporter from CNN estimated last week that less than half of the $175 billion figure is supported with documentation on DOGE's sites. Trump privately questioned whether Musk and DOGE could follow through on the amount of cuts they said they would make, according to a report in The Wall Street Journal Saturday. Unnamed officials in the administration told the Journal Trump asked, 'was it all bullshit?' and wondered if Musk could actually cut $1 trillion in government spending. Forbes estimates Musk has a net worth of about $422.7 billion as of Sunday morning, making him the wealthiest person in the world. Trump Defends Spending Bill After Musk Says It 'Undermines' DOGE Cuts (Forbes) Elon Musk on DOGE and why he doesn't want to "take responsibility for everything the administration's doing" (CBS News) Trump Defends Spending Bill After Musk Says It 'Undermines' DOGE Cuts (Forbes) Trump Questioned Extent Of Musk's DOGE Cuts, Report Says (Forbes)
Washington Post
26 minutes ago
- Washington Post
'Lilo & Stitch' passes 'Sinners' to become 2nd highest grossing film of 2025
'Lilo & Stich' and 'Mission: Impossible—The Final Reckoning' dominated the box office charts again after fueling a record-breaking Memorial Day weekend . Theaters in the U.S. and Canada had several new films to offer this weekend as well, including Sony's family friendly 'Karate Kid: Legends' and the A24 horror movie 'Bring Her Back. ' According to studio estimates Sunday, it added up to a robust $145 million post-holiday weekend that's up over 115% from the same timeframe last year.
